Charles River Laboratories International Price Target Raised to $64.00 at Jefferies Group (CRL)
Equities researchers at Jefferies Group hoisted their price target on shares of Charles River Laboratories International (NYSE:CRL) from $57.00 to $64.00 in a research report issued on Tuesday, American Banking News.com reports. Jefferies Group’s price target points to a potential upside of 14.24% from the stock’s previous close.
Charles River Laboratories International (NYSE:CRL) traded down 0.50% on Tuesday, hitting $56.02. 895,950 shares of the company’s stock traded hands. Charles River Laboratories International has a 1-year low of $38.76 and a 1-year high of $56.59. The stock has a 50-day moving average of $52.60 and a 200-day moving average of $47.97. The company has a market cap of $2.696 billion and a price-to-earnings ratio of 26.68.
Charles River Laboratories International (NYSE:CRL) last released its earnings data on Wednesday, October 30th. The company reported $0.79 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.70 by $0.09. The company had revenue of $292.10 million for the quarter, compared to the consensus estimate of $290.28 million. During the same quarter last year, the company posted $0.65 earnings per share. Charles River Laboratories International’s revenue was up 4.8% compared to the same quarter last year. Analysts expect that Charles River Laboratories International will post $2.88 EPS for the current fiscal year.
CRL has been the subject of a number of other recent research reports. Analysts at Raymond James upgraded shares of Charles River Laboratories International from an “underperform” rating to a “market perform” rating in a research note to investors on Wednesday, December 11th. Separately, analysts at Deutsche Bank initiated coverage on shares of Charles River Laboratories International in a research note to investors on Wednesday, November 20th. They set a “hold” rating and a $55.00 price target on the stock. Finally, analysts at Sterne Agee raised their price target on shares of Charles River Laboratories International from $56.00 to $60.00 in a research note to investors on Friday, November 1st. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $48.81.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.